Jump directly to main navigation Jump directly to content Jump to sub navigation

Institute of Novel and Emerging Infectious Diseases (INNT

In vivo efficacy studies of monoclonal antibodies and small molecules against SARS-CoV-2 and other relevant agents


Duration: 09/2021 – 09/2024

Funding: AbbVie Inc.


In cooperation between the FLI and AbbVie Inc., we test the in vivo efficacy of monoclonal antibodies and small molecules raised against the SARS-CoV-2 spike protein. The project which is based on an agreement is focused on alternative delivery of respective development candidates to support systemic treatment or as a stand-alone therapy.

For other candidates, in vitro data will be generated in alignment between AbbVie Inc. and FLI prior to in vivo testing in the Syrian Hamster SARS-CoV-2 model that has recently been established and validated at the FLI.

Furthermore, there is agreement to evaluate also potential therapeutic possibilities for other relevant infectious agents in the future.

Involved INNT scientists::

PD Dr. Anne Balkema-Buschmann

Collection of a mouth swab sample from a SARS-CoV-2 infected Syrian hamster (© FLI)